Advances in
eISSN: 2377-4290
Submit manuscript...
Mini Review Volume 16 Issue 2
The current management of conjunctival melanoma
Zelia M Correa, Carolina Valente, Gustavo Gameiro, Carlo Miguel Galang, José Lutzky
Received: July 20, 2026 | Published: August 5, 2026
Citation: Correa ZM, Valente C, Gameiro G, et al. The current management of conjunctival melanoma. Adv Ophthalmol Vis Syst. 2026;16(2):50-53. DOI: 10.15406/aovs.2026.16.00509
Abstract
Conjunctival melanoma (CM) is a rare but potentially aggressive ocular surface malignancy. CM maycarry mutations in genes like BRAF or NRAS as cutaneous melanomas but are unique because, althoughUV exposure is not thought to be the primary cause, UV exposure may contribute in some cases wherethe conjunctiva is exposed to sunlight. This manuscript reviews the current management of conjunctivalmelanoma from surgery to sentinel lymph node biopsy, checkpoint inhibitors, and impact of certaingenetic in the future management of CM.
Keywords: conjunctival melanoma, surgical resection, topical chemotherapy, checkpoint inhibitors, BRAF, NRAS
©2026 Correa, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.